Eli Lilly has launched LillyDirect, a direct-to-consumer platform for its weight-loss medications like Zepbound, bypassing traditional pharmacy benefit managers (PBMs). This integrated system includes online physician referrals and in-house pharmacy fulfillment, offering lower prices than PBMs and aiming to streamline the prescription process for patients. The move represents a significant shift in pharmaceutical sales, leveraging technology to create a more direct relationship with consumers and potentially challenging the established role of PBMs in the healthcare industry. AI
IMPACT This shift to direct-to-consumer sales and integrated software platforms by pharmaceutical companies may accelerate the adoption of AI in healthcare for patient management and prescription fulfillment.
RANK_REASON Product launch by a major pharmaceutical company that significantly alters distribution and pricing models. [lever_c_demoted from significant: ic=1 ai=0.4]
- CostPlus Drugs
- Eli Lilly
- LillyDirect
- Lilly Employer Connect
- Pharmacy Benefit Managers (PBMs)
- The Washington Post
- Virta Health
- Waltz Health
- Wegovy
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
